A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
NCT ID: NCT06906562
Last Updated: 2025-11-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
40 participants
INTERVENTIONAL
2025-08-26
2028-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pemigatinib in Subjects With Adenosquamous Carcinoma of the Pancreas
NCT05216120
Expanded Access of Pemigatinib to Treat a Single Patient With Metastatic Pancreatic Cancer
NCT03906357
Phase 2 Study of S-1 as 2nd Line Therapy in Metastatic Pancreatic Cancer
NCT00652054
Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer
NCT01956812
Panitumumab, Chemotherapy, and External-Beam Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot be Removed by Surgery
NCT00601627
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. To evaluate the efficacy of single agent pemigatinib in patients with advanced or metastatic pancreas cancer of any histologic classification with FGFR2 gene fusions/translocations.
II. To understand response rate and potential for pemigatinib to benefit patients who have other FGFR alterations including point mutations, extracellular small indels and kinase domain duplications in pancreas cancer.
SECONDARY OBJECTIVES:
I. To further evaluate the efficacy of single agent pemigatinib in each above cohort separately.
II. To characterize the safety and tolerability of single agent pemigatinib.
EXPLORATORY OBJECTIVE:
I. To evaluate dynamics of cell-free deoxyribonucleic acid (DNA) (cfDNA) optimized for monitoring response to pemigatinib and detecting emerging resistance mutations to pemigatinib.
OUTLINE: Patients receive pemigatinib orally (PO) once daily (QD) on days 1-14 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo blood sample collection, computed tomography (CT) and/or magnetic resonance imaging (MRI), and optical coherence tomography (OCT) throughout the study. Patients may also undergo whole body bone scans and dilated fundoscopy as clinically indicated. After completion of study treatment, patients are followed up at 30 days, then every 4 months for one year.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pemigatinib Treament
Patients receive pemigatinib PO QD on days 1-14 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo blood sample collection, CT and/or MRI, and OCT throughout the study. Patients may also undergo whole body bone scans and dilated fundoscopy as clinically indicated.
Pemigatinib
Pemigatinib will be taken orally with a targeted starting does of 13.5 mg
Computed Tomography (CT)
Undergo CT scan
Magnetic Resonance Imaging
Undergo MRI
Optical Coherence Tomography
Undergo OCT
Bone Scan
Undergo whole body bone scan
Ophthalmoscopy
Undergo dilated ophthalmoscopy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pemigatinib
Pemigatinib will be taken orally with a targeted starting does of 13.5 mg
Computed Tomography (CT)
Undergo CT scan
Magnetic Resonance Imaging
Undergo MRI
Optical Coherence Tomography
Undergo OCT
Bone Scan
Undergo whole body bone scan
Ophthalmoscopy
Undergo dilated ophthalmoscopy
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Written documentation of local or central Clinical Laboratory Improvement Act (CLIA)-certified laboratory determination of FGFR gene fusions/translocations or activating mutations
* The study is open to pancreatic cancer in the following cohorts:
* Cohort 1: Pancreatic cancer of any histology with FGFR2 fusion/translocation (n, up to 30) who have progressed on or are intolerant to at least one standard of care (SOC) therapy. Prior therapy with a different FGFR inhibitor is not permitted. Patients with concurrent Kirsten rat sarcoma (KRAS) mutations are excluded from this cohort
* Cohort 2: Pancreatic cancer of any histology with activating point mutations, fusion/translocation (FGFR1,3,4) extracellular small indels, or kinase domain duplications (n, up to 10). Patients must have progressed on or are intolerant to at least one SOC therapy. Prior therapy with a different FGFR inhibitor is not permitted. Patients with concurrent KRAS mutations are permitted in this cohort
* Evidence of measurable or evaluable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
* Patients must have received at least one prior SOC regimen for advanced/metastatic pancreas cancer. Patients should have had evidence of progressive disease following their prior regimen, or if prior treatment was discontinued due to toxicity must have continued evidence of measurable or evaluable disease. Patients who have received prior treatment with an alternate FGFR inhibitor are not eligible for the study
* Patients with symptomatic central nervous system (CNS) metastases are excluded (because it is unclear how much CNS penetration the drug has). However, asymptomatic patients with history of successfully treated CNS metastases with surgery or radiation and follow up imaging showing stability, can be eligible
* Patients ≥ 18 years of age of either gender
* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 (patients with ECOG performance status of 2 may be considered on a case-by-case basis after discussion with Incyte)
* Able to read and/or understand the details of the study and provide written evidence of informed consent as approved by Institutional Review Board (IRB)/Ethics Committee (EC)
* Recovery from adverse events of previous systemic anti-cancer therapies to baseline or Grade 1, except for:
* Alopecia
* Stable neuropathy of ≤ Grade 2 due to prior cancer therapy
* Able to swallow and retain oral medication
* Willing and able to comply with scheduled visits, treatment plan and laboratory tests
Exclusion Criteria
\* Note: Steroid use for management of CNS tumors is allowed but must be at a stable dose for at least 2 weeks preceding study entry
* History of another primary malignancy except adequately treated in situ carcinoma of the cervix or non-melanoma carcinoma of the skin or any other curatively treated malignancy that is not expected to require treatment for recurrence during the course of the study or affect survival
* Any other medical condition that would, in the investigator's , prevent the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures
* Current evidence of corneal or retinal disorder/keratopathy including, but not limited to, bullous/band keratopathy, corneal abrasion, inflammation/ulceration, keratoconjuctivitis, confirmed by ophthalmologic examination
* History and/or current evidence of extensive tissue calcification including, but not limited to, the soft tissue, kidneys, intestine, myocardium, and lung with the exception of calcified lymph nodes, minor pulmonary parenchymal calcifications, and asymptomatic coronary calcification
* Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral pemigatinib (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection)
* Current evidence of endocrine alterations of calcium/phosphate homeostasis, e.g., parathyroid disorders, history of parathyroidectomy, tumor lysis, tumoral calcinosis etc.
* Treatment with any of the following anti-cancer therapies prior to the first dose of pemigatinib within the stated timeframes:
* Cyclical chemotherapy (intravenous) within a period of time that is shorter than the cycle length used for that treatment (e.g., 6 weeks for nitrosourea, mitomycin-C)
* Biological therapy (e.g., antibodies - including bevacizumab) within a period of time that is ≤ 5 t1/2 or ≤ 4 weeks, whichever is shorter, prior to starting study drug
* Continuous or intermittent small molecule therapeutics within a period of time that is ≤ 5 t1/2 or ≤ 4 weeks (whichever is shorter) prior to starting study drug
* Any other investigational agents within a period of time that is ≤ 5 t1/2 or less than the cycle length used for that treatment or ≤ 4 weeks (whichever is shortest) prior to starting study drug
* Wide field radiotherapy (including therapeutic radioisotopes such as strontium 89) ≤ 4 weeks or limited field radiation for palliation ≤ 2 weeks prior to starting study drug
* Patients who are currently receiving treatment with agents that are known strong inducers or inhibitors of CYP3A4 and medications which increase serum phosphorus and/or calcium concentration are excluded. Patients are not permitted to receive enzyme-inducing anti-epileptic drugs
* Consumption of grapefruit, grapefruit juice, grapefruit hybrids, pomegranates, star fruits, pomelos, Seville oranges or products within 7 days prior to first dose
* Absolute neutrophil count (ANC) ≤ 1,000/mm\^3 \[1.0 x 10\^9/L\]
* Platelets ≤ 75,000/mm\^3 \[75 x 10\^9/L\] • Hemoglobin ≤ 9.0 g/dL
* Total bilirubin ≥ 1.5x upper limit of normal (ULN) unless associated with patient's primary cancer and/or metastases and with principal investigator's approval
* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≥ 3x ULN unless associated with patient's primary cancer and/or metastases and with principal investigator's approval
* Alkaline phosphatase ≥ 2.5x ULN unless associated with patient's primary cancer and/or metastases and with principal investigator's approval
* Calculated or measured creatinine clearance of \< 40 mL/min
* Calcium-phosphate homeostasis:
* Inorganic phosphorus outside of institutional normal limits
* Total serum calcium (can be corrected) outside of institutional normal limits
* History of clinically significant or uncontrolled cardiac disease including unstable angina, acute myocardial infarction, New York Heart Association Class III or IV congestive heart failure, or arrhythmia requiring therapy. Subjects with a pacemaker and well-controlled rhythm for at least 1 month prior to first dose will be allowed
* Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test
* Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 3 months following the discontinuation of study treatment. Highly effective contraception methods include:
* Total abstinence (when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception
* Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow-up hormone level assessment
* Male sterilization (at least 6 months prior to screening). For female patients on the study the vasectomized male partner should be the sole partner for that patient
* Use of oral, injected or implanted hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine systems (IUS), or other forms of hormonal contraception that have comparable efficacy (failure rate \<1%), for example hormone vaginal ring or transdermal hormone contraception In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment. Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least 6 weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow-up hormone level assessment is she considered not of child bearing potential
* Sexually active males unless they use a condom during intercourse while taking drug and for 3 months after the last dose of the study drug and should not father a child in this period. A condom is required to be used also by vasectomized men as well as during intercourse with a male partner in order to prevent delivery of the drug via seminal fluid
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Incyte Corporation
INDUSTRY
Sameek Roychowdhury
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sameek Roychowdhury
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sameek Roychowdhury, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Ohio State University Comprehensive Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ohio State University-Telemedicine
Birmingham, Alabama, United States
Ohio State University-Telemedicine
Mobile, Alabama, United States
Ohio State University-Telemedicine
Anchorage, Alaska, United States
Ohio State University-Telemedicine
Phoenix, Arizona, United States
Ohio State University-Telemedicine
Tucson, Arizona, United States
Ohio State University-Telemedicine
Hot Springs, Arkansas, United States
Ohio State University-Telemedicine
Los Angeles, California, United States
Ohio State University-Telemedicine
San Diego, California, United States
Ohio State University-Telemedicine
San Francisco, California, United States
Ohio State University-Telemedicine
Auroa, Colorado, United States
Ohio State University-Telemedicine
New Haven, Connecticut, United States
Ohio State University-Telemedicine
Wilmington, Delaware, United States
Ohio State University-Telemedicine
Washington D.C., District of Columbia, United States
Ohio State University-Telemedicine
Jacksonville, Florida, United States
Ohio State University-Telemedicine
Miami, Florida, United States
Ohio State University-Telemedicine
Orlando, Florida, United States
Ohio State University-Telemedicine
Tampa Bay, Florida, United States
Ohio State University-Telemedicine
Atlanta, Georgia, United States
Ohio State University-Telemedicine
Augusta, Georgia, United States
Ohio State University-Telemedicine
Honolulu, Hawaii, United States
Ohio State University-Telemedicine
Boise, Idaho, United States
Ohio State University-Telemedicine
Champaign, Illinois, United States
Ohio State University-Telemedicine
Chicago, Illinois, United States
Ohio State University-Telemedicine
Fort Wayne, Indiana, United States
Ohio State University-Telemedicine
Indianapolis, Indiana, United States
Ohio State University-Telemedicine
Des Moines, Iowa, United States
Ohio State University-Telemedicine
Iowa City, Iowa, United States
Ohio State University-Telemedicine
Kansas City, Kansas, United States
Ohio State University-Telemedicine
Wichita, Kansas, United States
Ohio State University-Telemedicine
Lexington, Kentucky, United States
Ohio State University-Telemedicine
New Orleans, Louisiana, United States
Ohio State University-Telemedicine
Bar Harbor, Maine, United States
Ohio State University-Telemedicine
Baltimore, Maryland, United States
Ohio State University-Telemedicine
Boston, Massachusetts, United States
Ohio State University-Telemedicine
Ann Arbor, Michigan, United States
Ohio State University-Telemedicine
Detroit, Michigan, United States
Ohio State University-Telemedicine
Minneapolis, Minnesota, United States
Ohio State University-Telemedicine
St Louis, Missouri, United States
Ohio State University-Telemedicine
Bozeman, Montana, United States
Ohio State University-Telemedicine
Omaha, Nebraska, United States
Ohio State University-Telemedicine
Las Vegas, Nevada, United States
Ohio State University-Telemedicine
Concord, New Hampshire, United States
Ohio State University-Telemedicine
Albuquerque, New Mexico, United States
Ohio State University-Telemedicine
Albany, New York, United States
Ohio State University-Telemedicine
New York, New York, United States
Ohio State University-Telemedicine
Syracuse, New York, United States
Ohio State University-Telemedicine
Charlotte, North Carolina, United States
Ohio State University-Telemedicine
Raleigh, North Carolina, United States
Ohio State University-Telemedicine
Bismarck, North Dakota, United States
Ohio State University-Telemedicine
Fargo, North Dakota, United States
Ohio State University-Telemedicine
Cincinnati, Ohio, United States
Ohio State University-Telemedicine
Cleveland, Ohio, United States
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
Ohio State University-Telemedicine
Oklahoma City, Oklahoma, United States
Ohio State University-Telemedicine
Portland, Oregon, United States
Ohio State University-Telemedicine
Philadelphia, Pennsylvania, United States
Ohio State University-Telemedicine
Pittsburgh, Pennsylvania, United States
Ohio State University-Telemedicine
Charleston, South Carolina, United States
Ohio State University-Telemedicine
Memphis, Tennessee, United States
Ohio State University-Telemedicine
Nashville, Tennessee, United States
Ohio State University-Telemedicine
Austin, Texas, United States
Ohio State University-Telemedicine
Dallas, Texas, United States
Ohio State University-Telemedicine
Houston, Texas, United States
Ohio State University-Telemedicine
San Antonio, Texas, United States
Ohio State University-Telemedicine
Salt Lake City, Utah, United States
Ohio State University-Telemedicine
Burlington, Vermont, United States
Ohio State University-Telemedicine
Norfolk, Virginia, United States
Ohio State University-Telemedicine
Richmond, Virginia, United States
Ohio State University-Telemedicine
Seattle, Washington, United States
Ohio State University-Telemedicine
Morgantown, West Virginia, United States
Ohio State University-Telemedicine
Milwaukee, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
The Ohio State University Comprehensive Cancer Center and James Cancer Hospital
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Related Links
Access external resources that provide additional context or updates about the study.
The Jamesline
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2025-03043
Identifier Type: REGISTRY
Identifier Source: secondary_id
OSU-23382
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.